

Checklist for Reporting Human Islet Preparations Used in Research

Adapted from Hart NJ, Powers AC (2018) Progress, challenges, and suggestions for using human islets to understand islet biology and human diabetes. *Diabetologia* <https://doi.org/10.1007/s00125-018-4772-2>.

Manuscript DOI: https://doi.org/10.2337/db20-1079.R1 (Example, https://doi.org/10.2337/db18-1234)	
Title: Inhibition of lncRNA TCONS_00077866 ameliorates the high stearic acid diet-induced mouse pancreatic β -cell inflammatory response by increasing miR-297b-5p to downregulate SAA3 expression	
Author list: Huimin Lu ¹ , Rui Guo ¹ , Yunjin Zhang, Shenghan Su, Qingrui Zhao, Yue Yu, Hongbo Shi, Haoran Sun, Yongjian Zhang, Shenglong Li, Dan Shi, Xia Chu, and Changhao Sun	
Corresponding author: Changhao Sun; Huimin Lu	Email address: changhaosun2002@163.com; lhm_519@sina.com

Islet preparation	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22
MANDATORY INFORMATION																						
Unique identifier	A5	A6	A7	A8	A9	A12	A10	A11	A1	A3	A4	A14	A16	A18	A19	A20	A23	A25	A26	A15	A21	A22
Donor age (years)	44	45	46	55	66	51	54	55	59	51	53	50	63	55	52	35	64	47	66	54	64	68
Donor sex (M/F)	F	F	F	M	M	F	M	M	M	F	F	F	F	M	F	F	F	M	M	M	F	M
Donor BMI (kg/m ²)	22.22	22.97	23.98	22.00	22.93	21.23	24.16	28.82	24.12	24.24	24.00	26.46	18.4	24.02	24.03	20.2	25.6	19.49	20.2	27.55	25	22.2

Donor history of diabetes? Yes/No	No	No	No	No	Yes	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	Yes
If Yes, complete the next two lines if this information is available																							
Diabetes duration (years)					30																		1 month
Glucose-lowering therapy at time of death ^c					Injection of insulin, oral administration of Empagliflozin Tablets (No death)																	Nutritional diet control	

RECOMMENDED INFORMATION

Donor cause of death	no death	no death	no death	no death	no death	no death	no death	no death	no death	no death	no death	no death	no death	no death	no death	no death	no death	no death	no death	no death	no death	no death	
Warm ischaemia time (h)																							
Cold ischaemia time (h)																							
Estimated purity (%)	>90	>90	>90	>90	>90	>90	>90	>90	>90	>90	>90	>90	>90	>90	>90	>90	>90	>90	>90	>90	>90	>90	
Estimated viability (%)	>80	>80	>80	>80	>80	>80	>80	>80	>80	>80	>80	>80	>80	>80	>80	>80	>80	>80	>80	>80	>80	>80	
Total culture time (h) ^d																							
Glucose-stimulated insulin secretion or other functional	PCR	PCR	PCR	PCR	PCR	PCR	PCR	PCR	PCR	PCR	PCR	PCR	PCR, Glucose-stimulated insulin secretion	PCR, Glucose-stimulated insulin secretion	PCR, Glucose-stimulated insulin secretion	PCR, Glucose-stimulated insulin secretion	PCR, Glucose-stimulated insulin secretion	PCR, Glucose-stimulated insulin secretion	PCR	PCR	PCR	PCR	

measur ement ^e													ulin sec reti on		ulin sec reti on		ulin sec reti on					
Handpic ked to purity? Yes/No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No
Additi onal notes																						

^aIf you have used more than eight islet preparations, please complete additional forms as necessary

^bFor example, IIDP, ECIT, Alberta IsletCore

^cPlease specify the therapy/therapies

^dTime of islet culture at the isolation centre, during shipment and at the receiving laboratory

^ePlease specify the test and the results